Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Expert Opin Biol Ther. 2010 Nov;10(11):1555-61. doi: 10.1517/14712598.2010.524923. Epub 2010 Oct 4.

Targeting B cells with biologics in systemic lupus erythematosus.

Author information

  • 1Lupus Research Laboratory, Division of Rheumatology, Department of Medicine, University of California Los Angeles, 1000 Veteran Avenue 32-59, Los Angeles, CA 90095-1670, USA. alacava@mednet.ucla.edu

Abstract

IMPORTANCE OF THE FIELD:

The use of biologics as immune modulators in several autoimmune diseases has provided new tools to the physician's therapeutic armamentiarium and has led to improved patients' outcomes and quality of life. By producing autoantibodies, B cells in systemic lupus erythematosus (SLE) are key players in the pathogenesis of the disease and in its clinical manifestations. Therefore, biologics that target B cells in SLE aim at reducing the activity of these cells for the induction of remissions and/or amelioration of disease activity, reduction of organ involvement, and limitation of the complications and side effects caused by immunosuppressive therapies.

AREAS COVERED IN THIS REVIEW:

This review describes the past and current clinical trials with B-cell-targeted biologics in SLE, to provide a historical perspective and the state-of-the-art on the topic.

WHAT THE READER WILL GAIN:

We review how the disappointment in the field from promising agents has been instrumental in providing valuable lessons leading to an improved design of new trials that are now giving encouraging results.

TAKE HOME MESSAGE:

In systemic lupus erythematosus (SLE), the use of B-cell-based biologics in clinical trials has shown both disappointment and promise.

PMID:
20919800
[PubMed - indexed for MEDLINE]
PMCID:
PMC2962556
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare Icon for PubMed Central
    Loading ...
    Write to the Help Desk